124 related articles for article (PubMed ID: 8041522)
1. A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers.
Köhler U; Schröder H; Augustin W; Sabel BA
Neurosci Lett; 1994 Mar; 170(1):99-102. PubMed ID: 8041522
[TBL] [Abstract][Full Text] [Related]
2. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
Schröder U; Schröder H; Augustin W; Sabel BA
J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
[TBL] [Abstract][Full Text] [Related]
3. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
4. Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats.
Bhargava HN
Neuropharmacology; 1984 Apr; 23(4):439-44. PubMed ID: 6145116
[TBL] [Abstract][Full Text] [Related]
5. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. II. No effect on denervation or neuroleptic-induced supersensitivity.
Staunton DA; Magistretti PJ; Shoemaker WJ; Deyo SN; Bloom FE
Brain Res; 1982 Jan; 232(2):401-12. PubMed ID: 6322915
[TBL] [Abstract][Full Text] [Related]
6. A dietary haloperidol regimen for inducing dopamine receptor supersensitivity in rats.
Frey JM; Morgan WW; Ticku MK; Huffman RD
Pharmacol Biochem Behav; 1987 Apr; 26(4):661-9. PubMed ID: 3602028
[TBL] [Abstract][Full Text] [Related]
7. Presynaptic dopamine receptors: insensitivity to kainic acid and the development of supersensitivity following chronic haloperidol.
Bannon MJ; Bunney EB; Zigun JR; Skirboll LR; Roth RH
Naunyn Schmiedebergs Arch Pharmacol; 1980 Jun; 312(2):161-5. PubMed ID: 6772975
[TBL] [Abstract][Full Text] [Related]
8. Chronic ascorbate potentiates the effects of chronic haloperidol on behavioral supersensitivity but not D2 dopamine receptor binding.
Pierce RC; Rowlett JK; Bardo MT; Rebec GV
Neuroscience; 1991; 45(2):373-8. PubMed ID: 1762684
[TBL] [Abstract][Full Text] [Related]
9. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol.
Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I
Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390
[TBL] [Abstract][Full Text] [Related]
10. Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity.
Jenner P; Hall MD; Murugaiah K; Rupniak N; Theodorou A; Marsden CD
Biochem Pharmacol; 1982 Feb; 31(3):325-8. PubMed ID: 7200363
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
Rajakumar G; Naas F; Johnson RL; Chiu S; Yu KL; Mishra RK
Peptides; 1987; 8(5):855-61. PubMed ID: 2893360
[TBL] [Abstract][Full Text] [Related]
12. Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined.
Rastogi SK; Rastogi RB; Singhal RL; Lapierre YD
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):153-64. PubMed ID: 6137027
[TBL] [Abstract][Full Text] [Related]
13. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
Lynch MR
Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
[TBL] [Abstract][Full Text] [Related]
14. Lithium effects on haloperidol-induced pre- and postsynaptic dopamine receptor supersensitivity.
Verimer T; Goodale DB; Long JP; Flynn JR
J Pharm Pharmacol; 1980 Sep; 32(9):665-6. PubMed ID: 6107377
[No Abstract] [Full Text] [Related]
15. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
Bhargava HN
Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
[TBL] [Abstract][Full Text] [Related]
16. Antagonizing effect of lithium on the development of dopamine supersensitivity in the tuberoinfundibular system.
Tanimoto K; Maeda K; Chihara K
Brain Res; 1982 Aug; 245(1):163-6. PubMed ID: 6811103
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.
Pert A; Rosenblatt JE; Sivit C; Pert CB; Bunney WE
Science; 1978 Jul; 201(4351):171-3. PubMed ID: 566468
[TBL] [Abstract][Full Text] [Related]
18. The effect of dopamine receptor agonist treatment on haloperidol-induced supersensitivity in mice.
Fayle P; Jackson DM; Jenkins OF; Lafferty PA
Pharmacol Biochem Behav; 1985 Nov; 23(5):715-20. PubMed ID: 4080755
[TBL] [Abstract][Full Text] [Related]
19. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity.
Creese I; Burt DR; Snyder SH
Science; 1977 Aug; 197(4303):596-8. PubMed ID: 877576
[TBL] [Abstract][Full Text] [Related]
20. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
Gordon JH; Diamond BI
Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
